Results 21 to 30 of about 7,464 (216)

An introduction to the Marburg virus vaccine consortium, MARVAC.

PLoS Pathogens, 2022
The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine "MARVAC" consortium representing leaders in the field of vaccine research and development aiming to facilitate a rapid response to this infectious ...
Robert W Cross, Ira M Longini, Stephan Becker, Karin Bok, David Boucher, Miles W Carroll, Janet V Díaz, William E Dowling, Ruxandra Draghia-Akli, James T Duworko, John M Dye, Michael A Egan, Patricia Fast, Amy Finan, Courtney Finch, Thomas R Fleming, Joan Fusco, Thomas W Geisbert, Anthony Griffiths, Stephan Günther, Lisa E Hensley, Anna Honko, Ruth Hunegnaw, Jocelyn Jakubik, Julie Ledgerwood, Kerstin Luhn, Demetrius Matassov, Jeffrey Meshulam, Emily V Nelson, Christopher L Parks, Roxana Rustomjee, David Safronetz, Lauren M Schwartz, Dean Smith, Paul Smock, Ydrissa Sow, Christina F Spiropoulou, Nancy J Sullivan, Kelly L Warfield, Daniel Wolfe, Courtney Woolsey, Roland Zahn, Ana María Henao-Restrepo, César Muñoz-Fontela, Andrea Marzi   +44 more
doaj   +3 more sources

Egyptian rousette bats maintain long-term protective immunity against Marburg virus infection despite diminished antibody levels

Scientific Reports, 2017
Although bats are natural reservoir hosts for numerous zoonotic viruses, little is known about the long-term dynamics of the host immune response following infection and how these viruses are maintained in nature.
Amy J. Schuh, Brian R. Amman, Tara K. Sealy, Jessica R. Spengler, Stuart T. Nichol, Jonathan S. Towner   +5 more
doaj   +1 more source

Regulation of Marburg virus (MARV) budding by Nedd4.1: a different WW domain of Nedd4.1 is critical for binding to MARV and Ebola virus VP40

Journal of General Virology, 2009
The VP40 matrix protein of Marburg virus (MARV) has been shown to be the driving force behind MARV budding, a process in which the PPPY L-domain motif of VP40 plays a critical role. Here, we report that Vps4B and Nedd4.1 play critical roles in MARV VP40-mediated budding.
Shuzo, Urata, Jiro, Yasuda
openaire   +2 more sources

Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans

Vaccines
Background/Objectives: Marburg virus (MARV) is the etiological agent of Marburg Virus Disease (MVD), a rare but severe hemorrhagic fever disease with high case fatality rates in humans.
Alina Tscherne, Georgia Kalodimou, Alexandra Kupke, Cornelius Rohde, Astrid Freudenstein, Sylvia Jany, Satendra Kumar, Gerd Sutter, Verena Krähling, Stephan Becker, Asisa Volz   +10 more
doaj   +1 more source

MARV therapeutics with protective efficacy in the NHP model.

, 2022
MARV therapeutics with protective efficacy in the NHP model.
César Muñoz-Fontela (316931), Stephan Becker (146493), Ana María Henao-Restrepo (11943889), Demetrius Matassov (12667337), Janet V. Díaz (13955095), Dean Smith (3115575), David Boucher (3252372), Joan Fusco (12963755), Ruth Hunegnaw (6477422), David Safronetz (119343), Amy Finan (13955098), Roland Zahn (113319), Emily V. Nelson (13955113), Anthony Griffiths (4576210), Karin Bok (215710), Michael A. Egan (12667331), John M. Dye (131085), Roxana Rustomjee (164864), Kelly L. Warfield (8713173), Julie Ledgerwood (13955107), Lauren M. Schwartz (11185876), Jeffrey Meshulam (13955110), Christopher L. Parks (10308245), Ydrissa Sow (13804740), Nancy J. Sullivan (10272899), Lisa E. Hensley (7164947), Kerstin Luhn (74670), James T. Duworko (13804785), Ruxandra Draghia-Akli (49845), Christina F. Spiropoulou (8067347), Robert W. Cross (9239733), Ira M. Longini (9501539), Paul Smock (13955116), Andrea Marzi (146489), Thomas R. Fleming (13955104), William E. Dowling (11943877), Patricia Fast (145172), Jocelyn Jakubik (1425964), Daniel Wolfe (13955119), Stephan Günther (218223), Courtney Finch (13955101), Miles W. Carroll (8532708), Thomas W. Geisbert (9239748), Anna Honko (297045), Courtney Woolsey (9254949)   +44 more
core   +1 more source

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

Advanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin, Saurabh Singh, Soumya Chatterjee, Guang‐Zhi Sui, Yi‐Fu Wang, Ya‐Ting Lu, Yu‐Ling Lee, Kun‐Yuan Lin, Joy Khag, Ta‐Yu Liu, Shao‐Han Chang, Wai‐Mui Cheung, Hsiao‐Chin Hong, Ren‐Jun Hsu, Chen‐Yang Shen, Chia‐Wei Li, Weng‐Lang Yang, Yao‐Ming Chang, Shih‐Yu Chen, Chandan Guha, Shu‐Ping Wang   +20 more
wiley   +1 more source

Marburg Virus Infection in Egyptian Rousette Bats, South Africa, 2013–2014

Emerging Infectious Diseases, 2018
We detected a high seroprevalence of Marburg virus (MARV) antibodies in fruit bats in South Africa; 19.1% of recaptured bats seroconverted. The MARV RNA isolated closely resembled the 1975 Ozolin strain.
Janusz T. Pawęska, Petrus Jansen van Vuren, Alan Kemp, Nadia Storm, Antoinette A. Grobbelaar, Michael R. Wiley, Gustavo Palacios, Wanda Markotter   +7 more
doaj   +1 more source

Strain‐Tunable Photoluminescence From Ge Quantum Dots on Si Nanotips for CMOS‐Compatible Photonics

Advanced Physics Research, EarlyView.
This work studies strain in Ge quantum dots grown on Si nanotips using photoluminescence, X‐ray diffraction, and band structure calculations. It shows how emission changes with dot size, evaluates strain in the dot and substrate, and explains the role of direct and indirect transitions in the optical behavior.
Diana Ryzhak, Johannes Aberl, Enrique Prado‐Navarrete, Lada Vukušić, Oliver Skibitzki, Petr Klenovský, Marvin Hartwig Zoellner, Markus Andreas Schubert, Moritz Brehm, Davide Spirito, Giovanni Capellini   +10 more
wiley   +1 more source

A Single Amino Acid Change in the Marburg Virus Glycoprotein Arises during Serial Cell Culture Passages and Attenuates the Virus in a Macaque Model of Disease

mSphere, 2018
Marburg virus (MARV) causes disease with high case fatality rates, and there are no approved vaccines or therapies. Licensing of MARV countermeasures will likely require approval via the FDA’s Animal Efficacy Rule, which requires well-characterized ...
Kendra J. Alfson, Laura E. Avena, Jenny Delgado, Michael W. Beadles, Jean L. Patterson, Ricardo Carrion, Anthony Griffiths   +6 more
doaj   +1 more source

Comparison of EBOV and MARV pathophysiology over time.

, 2022
EBOV, Ebola virus; MARV, Marburg virus; NHP, nonhuman primate.
Christopher D. Kane (8592750), David L. Saunders (8699277), Catherine A. Bigger (12213596), Patrick L. Iversen (12213599), Mark R. Hickman (8951750)   +4 more
core   +1 more source